Demographics and baseline comorbidities of overall cohort, treatment groups of aspirin only, dual antiplatelet therapy (DAPT) with clopidogrel, DAPT with prasugrel or ticagrelor, and no antiplatelet
| Overall | Aspirin | DAPT.C | DAPT.PT | No antiplatelet | p-value aspirin versus no antiplatelet | P value aspirin versus DAPT.C | P value DAPT.C versus DAPT.PT | |
| N=14 716 | N=5888 | N=6888 | N=973 | N=783 | ||||
| Male | 9532 (64.8) | 3063 (52.0) | 5154 (74.8) | 831 (85.4) | 378 (48.3) | 0.053 | <0.001 | <0.001 |
| Age, mean (SD) | 70.2 (13.8) | 76.4 (12.3) | 65.3 (12.6) | 60.1 (9.8) | 79.2 (12.3) | <0.001 | <0.001 | <0.001 |
| Type of ACS | 0.755 | <0.001 | <0.001 | |||||
| UA | 6238 (42.4) | 3331 (56.6) | 2234 (32.4) | 132 (13.6) | 454 (58.0) | |||
| NSTEMI | 5011 (34.1) | 1892 (32.1) | 2498 (36.3) | 311 (32.0) | 243 (31.0) | |||
| STEMI | 3467 (23.6) | 665 (11.3) | 2156 (31.3) | 530 (54.5) | 86 (11.0) | |||
| Baseline comorbidities | ||||||||
| HTN | 3829 (26.0) | 2027 (34.4) | 1345 (19.5) | 102 (10.5) | 300 (38.3) | 0.035 | <0.001 | <0.001 |
| DM | 2920 (19.8) | 1518 (25.8) | 1093 (15.9) | 80 (8.2) | 192 (24.5) | 0.474 | <0.001 | <0.001 |
| HF | 1445 (9.8) | 950 (16.1) | 322 (4.7) | 14 (1.4) | 140 (17.9) | 0.234 | <0.001 | <0.001 |
| CKD | 776 (5.3) | 425 (7.2) | 253 (3.7) | 10 (1.0) | 72 (9.2) | 0.056 | <0.001 | <0.001 |
| Liver disease | 132 (0.9) | 50 (0.9) | 61 (0.9) | 3 (0.3) | 16 (2.0) | 0.008 | 0.9 | 0.135 |
| Arrhythmia | 446 (3.0) | 262 (4.5) | 134 (2.0) | 10 (1.0) | 36 (4.6) | 0.923 | <0.001 | 0.074 |
| Dyslipidaemia | 1377 (9.4) | 658 (11.2) | 586 (8.5) | 49 (5.0) | 62 (7.9) | 0.01 | <0.001 | 0.001 |
| Ischaemic stroke | 612 (4.2) | 337 (5.7) | 194 (2.8) | 16 (1.6) | 54 (6.9) | 0.218 | <0.001 | 0.053 |
| Haemorrhagic stroke | 135 (0.9) | 85 (1.4) | 22 (0.3) | 2 (0.2) | 25 (3.2) | 0.001 | <0.001 | 0.76 |
| IHD | 2565 (17.4) | 1302 (22.1) | 1004 (14.6) | 72 (7.4) | 143 (18.3) | 0.016 | <0.001 | <0.001 |
| Prior episode of ACS | 1125 (7.6) | 581 (9.9) | 433 (6.3) | 32 (3.3) | 65 (8.3) | 0.184 | <0.001 | <0.001 |
| Anaemia | 1129 (7.7) | 659 (11.2) | 284 (4.1) | 15 (1.5) | 147 (18.8) | <0.001 | <0.001 | <0.001 |
| History of bleeding | 1388 (9.4) | 687 (11.7) | 489 (7.1) | 41 (4.2) | 153 (19.5) | <0.001 | <0.001 | 0.001 |
| During index hospitalisation | ||||||||
| GP IIb/IIIa | 743 (5.1) | 4 (0.1) | 469 (6.8) | 262 (26.9) | 0 | 1 | <0.001 | <0.001 |
| Fibrinolytics | 238 (1.6) | 43 (0.7) | 166 (2.4) | 23 (2.4) | 4 (0.5) | 0.773 | <0.001 | 1 |
| PCI | 3327 (22.6) | 21 (0.4) | 2586 (37.5) | 695 (71.4) | 1 (0.1) | 0.505 | <0.001 | <0.001 |
| CABG | 499 (3.4) | 227 (3.9) | 188 (2.7) | 72 (7.4) | 6 (0.8) | <0.001 | <0.001 | <0.001 |
| Concurrent medication during index hospitalisation discharge | ||||||||
| H2RA | 6117 (41.6) | 2726 (46.3) | 2776 (40.3) | 308 (31.7) | 248 (31.7) | <0.001 | <0.001 | <0.001 |
| PPI | 5915 (40.2) | 2276 (38.7) | 2643 (38.4) | 573 (58.9) | 349 (44.6) | 0.002 | 0.756 | <0.001 |
| OAC | 520 (3.5) | 248 (4.2) | 150 (2.2) | 5 (0.5) | 104 (13.3) | <0.001 | <0.001 | 0.001 |
Data are shown as frequency (percentage) unless specified. Multiple comparison was done among the presented groups. Only adjusted p value for comparison between (1) aspirin and no antiplatelet group; (2) aspirin and DAPT with clopidogrel group; and (3) DAPT with clopidogrel and DAPT with prasugrel or ticagrelor, were shown.
ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; DAPT.C, dual antiplatelet therapy with clopidogrel; DAPT.PT, dual antiplatelet therapy with prasugrel or ticagrelor; DM, diabetes; HF, heart failure; H2RA, histamine-2 receptor antagonist; HTN, hypertension; IHD, ischaemic heart disease; GP IIb/IIIa, glycoprotein IIb/IIIa receptor inhibitor; NSTEMI, non-ST-elevation myocardial infarction; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; STEMI, ST-elevation myocardial infarction; UA, unstable angina.;